tbuckley/cabot-search huggingface dataset:
Hepatitis B reactivation with pembrolizumab, atezolizumab, and nivolumab: A pharmacovigilance study and literature review.
Authors: Ibrahim Muhsen, Ethan Burns, Godsfavour Umoru, Abeer Arain, Jiaqiong Xu, Maen Abdelrahim
Journal: Journal of Clinical Oncology (2020)

e15127 Background: Chronic Hepatitis B virus (HBV) impacts 257 million people worldwide. Chemo- and immunotherapies may predispose to HBV reactivation (HBVr), which can negatively impact oncologic outcomes. Programmed death (PD) and programmed death ligand (PDL)-1 inhibitors have been implicated in HBVr. The aim of this study is to report HBVr in patients who are treated with PD-1/PD L-1 inhibitors by utilizing the FDA Adverse Events Reporting System (FAERS) and literature review. Methods: This is a retrospective pharmacovigilance study using FAERS. We reviewed cases of HBVr reported in patients treated with pembrolizumab, atezolizumab, and nivolumab from 2016-2019. Signal disproportionality analysis was conducted using a reporting odds ratio (ROR). A systematic review using Ovid MEDLINE(R) was conducted for additional reports of HBVr and associated outcomes. Results: There were 15 cases of HBVr associated with the use of PD1/PDL1 inhibitors on FAERS (ROR 1.2, 95% CI [0.72-1.99]). Only pembrolizumab was shown to a have significant association with HBVr (ROR 2.93, 95% CI [1.57-5.46]) (Table). Moreover, 7 cases of HBVr were reported in the literature, 3 with pembrolizumab and 4 with nivolumab. Median time to diagnosis following initiation of immunotherapy was 12 (5-24) weeks and 8 (3-10.5) weeks for resolution of HBVr. Conclusions: Pembrolizumab was the only agent with a significant association of HBVr. Future institutional studies in both endemic and nonendemic areas are warranted to determine the true incidence and necessity of pretreatment screening for HBV in patients on PD-1/PDL-1 therapy. [Table: see text]
Oncolytic virus pelareorep plus carfilzomib phase I trial in carfilzomib-refractory patients (NCI 9603): Responses with cytokine storm.
Authors: Douglas Weston Sborov, Domenico Viola, Ada A Dona, Ajay K. Nooka, Jonathan L. Kaufman, Sagar Lonial, Lawrence Boise, Madhav V. Dhodapkar, Nisha Joseph, Flavia Pichiorri, Craig C. Hofmeister
Journal: Journal of Clinical Oncology (2020)

8535 Background: Viral oncolytic therapy with intravenous Pelareorep, the infusible form of reovirus, is supported by preclinical data indicating that its antitumor activity results from direct cytolysis and an immune response against infected MM cells. Our preclinical data has shown that monocytes serve as carriers of reovirus from the peripheral blood to the bone marrow (Dona et al, ASH, 2019). In this abstract we present patients treated to date that were Carfilzomib refractory at enrollment. Methods: Pelareorep (P), Carfilzomib (K), and dexamethasone (d) were all infused on days 1, 2, 8, 9, 15 and 16 of a 28-day cycle. Patients were pretreated with dexamethasone 20 mg intravenously, then Carfilzomib 20 mg/m 2 on days 1 and 2 of cycle 1, and 56 mg/m 2 thereafter. Pelareorep dose levels were at 3x10 10 , 4.5*10 10 , and planned 9*10 10 median tissue culture infectious dose (TCID 50 ). Results: All 6 evaluable patients showed reovirus infection in the post-treatment marrow aspirates cycle 1 day 9. Despite all patients having Carfilzomib-refractory disease, 2 patients achieved partial responses, two patients with short duration stable disease but few side effects, and 2 patients with PD. Of the two responders, one patient developed fever and grade 4 thrombocytopenia during cycle 1 and withdrew mid cycle. The other patient with a PR developed a cytokine storm - this patient presented cycle 1 day 3 hypoxemic with pneumonia, systolic failure (LVEF 69%-- &gt; 26%), with biochemical evidence of hemophagocytic syndrome with elevated IL-2R, IL-6, and ferritin &gt; 25K. This patient responded to tocilizumab, but ultimately died two weeks later with sepsis. Autopsy revealed pneumonia, no areas of reovirus infection other than in myeloma cells, and reovirus productive infection in 5-35% of myeloma cells (i.e. capsid protein). Conclusions: While infection of myeloma cells was seen in all evaluable patients on cycle 1 day 9, those with a clinical response demonstrated concomitant CD8 &amp; NK cell recruitment, PD L1 upregulation, activated caspase-3 expression, increased viral protein production within the myeloma cells, and these patients demonstrated mild to severe signs and symptoms consistent with secondary HLH. This is the first report of cytokine storm after oncolytic virus in a patient with a blood cancer, a syndrome thought to be related to T-cell activation from the combination treatment. This trial was supported by the NCI Division of Cancer Treatment &amp; Diagnosis Cancer Therapy Evaluation Program (CTEP). Clinical trial information: NCT02101944 .
Craniospinal irradiation in patients diagnosed with glioblastoma with primitive neuronal component prevents distant intracranial and leptomeningeal recurrences.
Authors: Boryana M Eastman, Patrick J Cimino, Tresa McGranahan, Lia Moriguchi Halasz
Journal: Journal of Clinical Oncology (2020)

e14540 Background: Glioblastoma (GBM) is the most common primary central nervous system (CNS) malignancy. In recent years, molecular and histological analyses have identified GBM with primitive neuronal component (GBM-PNC) as a distinct entity with poor regional control and worse overall prognosis. GBM-PNCs are more prone to CNS dissemination and leptomeningeal (LM) metastasis, occurring in up to 40% of patients. Given the concern for distal CNS spread, we hypothesized that craniospinal irradiation (CSI) may be an effective treatment option for GBM-PNC. Methods: We performed a retrospective chart review of patients diagnosed with GBM-PNC treated at a large academic center with institutional review board approval. Clinical, histologic and treatment characteristics, as well as disease outcomes were obtained from the electronic medical record. Results: Ten patients diagnosed with GBM-PNC were identified in the period of 2005-2019. Median follow-up was 17 months. Overall, 80% of patients were men, median age was 49 years (range 20-64) and ECOG 0-1. Fifty percent of patients received CSI as opposed to involved field radiation therapy (IFRT). Four of five patients receiving CSI were treated with proton therapy. All patients, but one received concurrent Temozolomide. Both IFRT and CSI were tolerated well with minimal grade 3-4 toxicities. Patients treated with CSI were more likely to experience transient grade 3-4 lymphopenia (60% vs 0%). Eighty percent of patients experienced a recurrence after treatment with median progression free survival (PFS) of 13 months (range 8-26). PFS did not differ between patients receiving IFRT and CSI (14 vs 12.5 months, p = 0.9). Median overall survival (OS) was 30 months for patients who received IFRT, and median OS was not reached in the CSI group. Of the patients who received CSI as part of their treatment, all recurrences were within the high dose radiation area. On the contrary, 75% of patients who received IFRT experienced multiple recurrences at new intracranial sites and later in the leptomeninges or the spine, requiring multiple treatment courses. Conclusions: This hypothesis generating study demonstrates that CSI may prevent distant intracranial metastasis and LM disease progression. CSI delivered with proton therapy was well tolerated with minimal additional toxicity. A larger study is needed to guide the optimal treatment of patients diagnosed with glioblastoma with primitive neuronal component.
多发动脉粥样硬化致无脉症一例
Authors: 于俊英, 于福玲, 刘凤芹
Journal: BMJ (2005)

患者,男,69岁,因间断胸痛、气短10余年,加重伴浮肿并发现无脉1个月,于2002年8月26日入院.之前3年曾检查发现患腔隙性脑梗死.体格检查:体温36.5℃,呼吸20次/min,上、下肢血压测不出. 神志清,口唇微绀,双肺呼吸音粗,心界扩大,心率98次/min,律齐,二尖瓣听诊区可闻及收缩期3/6级杂音,肝脾无肿大,双踝部呈凹陷性水肿,四肢肌力未见异常,双上肢桡动脉及双足背动脉未扪及搏动。
疑诊无形体病七例
Authors: 刘庆辉
Journal: BMJ (2011)

无形体病(human granulocytic anaplasmosis,HGA)是由人粒细胞无形体引起的经蜱传播的新发人兽共患自然疫源性疾病[1],临床医生对该类疾病认识不足,普遍存在漏诊和误诊[2].我院近2年疑似一些患者,但有明确蜱叮咬史者却少,2009年至2010年有7例具有明确蜱叮咬史,报道如下。
Abstract 20717: Restarting Oral Anticoagulant Therapy After Major Bleeding Events in Atrial Fibrillation: A Systematic Review and Meta-Analysis of Real-World Studies
Authors: Marco Proietti, Giulio F Romiti, Imma Romanazzi, Alessio Farcomeni, Laila Staerk, Peter B Nielsen, Gregory Y Lip
Journal: Circulation (2017)

Introduction: Use of oral anticoagulant (OAC) therapy in stroke prevention in atrial fibrillation (AF) is associated with an inherited risk of bleeding. The benefits and risks of OAC restarting aft...
Association of elevated red cell distribution width and overall survival in multiple myeloma.
Authors: Sam Rubinstein, Elizabeth Sigworth, Qingxia M Chen, Sandip Chaugai, Robert F. Cornell, Jeremy Lyle Warner
Journal: Journal of Clinical Oncology (2020)

8534 Background: The most widely used multiple myeloma (MM) staging system, the Revised International Staging System (R-ISS), is based on lactate dehydrogenase, albumin, cytogenetics, and beta-2 microglobulin (B2M). B2M has limited clinical utility, is often only obtained to compute R-ISS, and is often a send-out test. Prior studies have shown that elevated red cell distribution width (RDW), a common test that is part of the routine complete blood count, is associated with reduced overall survival (OS) in MM. We hypothesized that a MM staging system could be constructed replacing B2M with RDW. Methods: Patients treated at Vanderbilt University Medical Center from 2000 to 2018 with cancer registry-confirmed MM diagnoses were included. OS was computed by registry-curated death and diagnosis dates; living patients were censored at date last known alive or of last follow up. A Cox proportional hazards model determining the independent effects of R-ISS, age, and RDW on OS was built. An alternate staging system (RDW-SS) was developed, replacing the B2M cutoffs in R-ISS with RDW (stage 1: RDW &lt; 14.0% stage 2: RDW 14.0-15.5%; stage 3: RDW &gt; 15.5%). Cox models comparing RDW-SS and R-ISS after adjustment for age and category of induction therapy (proteasome inhibitor [PI] and immunomodulatory drug [IMiD]), PI only, IMiD only, other) were built. Results: In 604 MM patients with available data, RDW was independently associated with OS after adjustment (HR = 1.069 per 1% RDW increase, p &lt; 0.001). RDW-SS stages were associated with reduced OS (RDW-SS 2 HR 1.52, 95% CI 1.09 – 2.11, p = 0.01; RDW-SS 3 HR 2.13, 95% CI 1.37 – 3.28, p &lt; 0.001) after adjustment; R-ISS stages were not (Table). Conclusions: RDW at MM diagnosis was independently associated with reduced OS, after adjustment for the clinical factors of age and treatment exposure; notably, R-ISS was not. The RDW-SS is simpler to obtain than R-ISS and may have improved prognostic value pending independent validation. If confirmed, mechanistic study of the etiology of this relationship is warranted. [Table: see text]
Clinical characteristics of patients with coronary artery disease complicated with metabolic syndrome and their correlation with severity of coronary stenosis
Authors: 米树华, 陶红, 赵全明, 田磊, 王南晔, 郑虹
Journal: BMJ (2005)

目的 分析冠心病合并代谢综合征患者的临床特征和冠状动脉病变特点.方法回顾性分析本院175例冠心病患者的临床资料及冠状动脉造影结果,按照ATP Ⅲ诊断标准分为代谢综合征组和无代谢综合征组,以冠状动脉病变积分评价其病变程度.结果 175例中89例(50.9%)合并代谢综合征.代谢综合征组的体重指数、腰围、总胆固醇、甘油三酯、尿酸、空腹血糖、餐后2 h血糖、糖化血红蛋白、稳态模型的胰岛素抵抗指数及心肌梗死的发生率均显著高于无代谢综合征组,而高密度脂蛋白胆固醇水平显著低于后者;其冠状动脉多支病变发生率(65.1%比45.4%,P<0.01)及冠状动脉病变总积分均显著高于无代谢综合征组(7.5±3.6比6.4±3.3,P<0.05);代谢综合征组中合并糖尿病患者的冠状动脉病变总积分也高于无糖尿病患者(8.0±3.7比6.3±3.5,P<0.05).相关分析显示,冠状动脉病变程度与患者的腰围、总胆固醇、甘油三酯、糖化血红蛋白、空腹血糖及餐后2 h血糖水平呈明显正相关(P<0.05),与高密度脂蛋白胆固醇呈负相关(P<0.01).结论冠心病患者中合并代谢综合征较为普遍,且合并代谢综合征患者的冠状动脉病变呈多支性、狭窄程度更高,应进行全面心血管危险因素防治,以改善预后。
Questions prompt lists used by palliative care teams help trigger discussions on prognosis and end-of-life issues with advanced cancer patients.
Authors: Carole Bouleuc, Alexis Burnod, Paul H. Cottu, Jean-Yves Pierga, Sylvie Dolbeault
Journal: Journal of Clinical Oncology (2020)

12110 Background: Accuracy of prognosis perception is a key element to allow advanced cancer patients to make informed decisions and to reflect on their end-of-life priorities. This study aims to explore whether a question prompt list can promote discussions on prognosis and end-of-life issues during palliative care consultations for advanced cancer patients. Methods: In this multicentric randomised study, patients assigned in the interventional arm receive a question prompt list during the first palliative care consultation (T1) after referral by oncologists. The primary endpoint is the number of questions asked by patients during the second palliative care consultation (T2) one month later. Secondary objectives are anxiety and depression, quality-of-life, satisfaction with care, coping assessed at baseline (T1) and at two months (T3). Palliative care teams from 3 french comprehensive cancer centers participate in the study. Main inclusion criteria were adult patients with metastatic non-haematological cancer referred to the palliative care team and with an estimated life expectancy less than one year. Results: Patients (n = 71) in the QPL arm asked more questions (mean 21.8 versus 18.2, p-value = 0.03) during the palliative care consultations compared to patients in the control arm (n = 71). These questions addressed palliative care (mean 5.6 versus 3.7, p-value = 0.012) and end-of-life issues (mean 2.2 versus 1, p = 0.018) more frequently than in the control arm. At two months, compared to baseline, there was no change in anxio-depressive symptoms or quality of life. Conclusions: QPL favours discussion on prognosis and end-of-life care during the palliative care consultations for advanced cancer patients. Clinical trial information: NCT02854293 .
Ivosidenib (IVO) prior to hematopoietic cell transplant for patients with <i>IDH1</i>-mutant relapsed or refractory acute myeloid leukemia <i>(</i>R/R AML).
Authors: Courtney Denton Dinardo, Eytan Stein, Arnaud Pigneux, Jessica K. Altman, Robert Collins, Harry Paul Erba, Justin M. Watts, Geoffrey L. Uy, Stephanie M. Kapsalis, Hua Liu, Thomas Winkler, Gail J. Roboz, Stéphane de Botton
Journal: Journal of Clinical Oncology (2020)

7521 Background: Allogeneic hematopoietic cell transplantation (HCT) provides a potentially curative option for patients (pts) with R/R AML. Disease status at the time of transplant is a major determinant of long-term prognosis, with pts typically receiving salvage chemotherapy prior to HCT to induce a remission. However, older and/or heavily pre-treated pts frequently cannot tolerate intensive chemotherapy (IC) or do not obtain adequate disease control to permit an HCT. IVO is an oral, potent, targeted inhibitor of mutant IDH1 (mIDH1) approved for the treatment of adults with newly diagnosed AML ≥75 y of age or ineligible for IC, and those with R/R AML. We assessed HCT outcomes in pts with m IDH1 R/R AML who proceeded to HCT after treatment with IVO in a phase I study (NCT02074839). Methods: Baseline characteristics, clinical response (including CR, CRi/CRp, MLFS), and overall survival (OS) for the subgroup of pts with m IDH1 R/R AML who received IVO 500 mg QD, responded to treatment and then underwent HCT are reported. m IDH1 variant allele frequency (VAF) from bone marrow mononuclear cells was assessed using BEAMing digital PCR (0.02–0.04% VAF detection limit). Results: Among 179 pts with R/R AML treated with IVO, 18 proceeded to HCT: median age, 61.5 y (range 36–68); 56% male; 16.7% had secondary AML; 27.8% had ≥3 prior regimens; 11.1% had a prior HCT. The median duration of IVO treatment prior to HCT was 3.9 mo (range 2.1–15.2). The last reported response prior to HCT was 50.0% CR. Six- and 12-mo post-HCT survival rates were 77.8% and 50.0%; median relapse-free survival post HCT was 7.3 mo (range 2.6–NE). Median OS from start of IVO was 16.8 mo (95% CI 9.2, NE) for HCT pts vs 9.0 mo (95% CI 7.1, 10.2) in the entire study cohort; median follow-up time, 33.2 mo (range 3.2–41.9). Eight HCT pts were censored for OS: 5 are in remission, 2 relapsed and are in survival follow-up, and 1 was lost to follow-up. Median OS was not estimable (95% CI 9.1, NE) for the 12 HCT pts who achieved CR after IVO therapy and was 20.5 mo (95% CI 16.4, NE) for the 31 CR pts who did not undergo HCT. m IDH1 was undetectable in 1/18 (6%) pts; 4/18 (22%) pts had reduction below 1% VAF in ≥1 at the last assessment prior to HCT. Conclusions: IVO monotherapy is a putative treatment option to induce remissions prior to HCT for m IDH1 R/R AML pts who are not considered candidates for intensive salvage therapy. Post-transplant survival rates are encouraging and warrant further investigation of IVO monotherapy or combination salvage therapies prior to HCT. Clinical trial information: NCT02074839 .
坏死性淋巴结炎14例临床分析
Authors: 支成斌, 李祥翠, 韦毅, 陈光蓉
Journal: BMJ (2005)

坏死性淋巴结炎是一种原因不明的淋巴结炎症反应性疾病,是一种有自愈倾向的良性疾病,本病又称组织细胞坏死性淋巴结炎、假淋巴瘤样增生、亚急性坏死性淋巴结炎、无粒性白细胞浸润性淋巴结炎等.最早(1972年)由Kikuchi和Fujimoto所描述,故又名Kikuchi-Fujimoto淋巴结炎或Kikuchi病.欧美少见,日本和我国多见[1].常易被误诊为淋巴瘤或其他恶性肿瘤.我们在四川大学华西附一院感染科进修期间,总结了该院1995年1月至2002年1月收治的11例经淋巴结活检及免疫组化染色证实的坏死性淋巴结炎,和我院1998年1月至2002年12月收治的3例经淋巴结活检证实为坏死性巴结炎的病例共14例,现报告如下。
浅析物理诊断学教学改革
Authors: 吴东, 潘慧, 朱峰
Journal: BMJ (2011)

美国医学生中流传着一句笑话:你认为谁诊断肺炎更准确,是手执听诊器的威廉·奥斯勒爵士,还是一台X光机?威廉·奥斯勒爵士(Sir William Osler,1849-1919)被称为北美现代医学之父,一生发表文章1600余篇,曾长期担任霍普金斯大学医学院院长,是公认的物理诊断大师.谁也没想到,百年之后威廉·奥斯勒爵士诊断肺炎的能力居然受到医学生的揶揄,老爵士地下有知,不知道会不会气得吹胡子。
Effects of valsartan on plasma resistin and microinflammation in patients with maintenance hemodialysis
Authors: Yan-fang Song, Hong Zhang, Yan Xu, Qi-feng Zhang
Journal: BMJ (2010)

In total, 106 patients with maintenance hemodialysis (MHD) were divided into two groups based on their valsartan administration, and 53 healthy controls were recruited in the study. Plasma concentrations of interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), resistin and high sensitivity C-reactive protein (hs-CRP) were measured by enzyme-linked immunosorbent assay (ELISA) before and after valsartan treatment. Plasma levels of resistin, IL-6, TNF-α and hs-CRP were all significantly increased in patients with MHD as compared to those in healthy controls (P＜0. 05). Among patients with MHD the plasma levels of resistin, IL-6 and hs-CRP in valsartan group were lower than those in non-valsartan group (P＜0. 05).

Key words: 
Renal dialysis; Valsartan
Effectiveness of swallowing training in patients with dysphagia after acute stroke
Authors: Yu-lan Chen
Journal: BMJ (2012)

Sixty patients with dysphagia following the acute stroke were enrolled and divided into training group and control group with 30 cases in each group.Both groups received the routine medication,but patients in training group had additional swallowing rehabilitation training.After 4 weeks,the recovery rate of swallowing function in training group was higher than that in control group [ 93 ％ (28/30) vs.63 ％(19/30),P ＜ 0.05 ] ; the incidence rate of aspiration pneumonia in training group was lower than that in control group[ 3.3％ ( 1/30 ) vs.26.7％ ( 8/30 ),P ＜ 0.05 ].The results showed that swallowing training applied to acute stroke patients with dysphasia may promote the recovery of swallowing function,reduce the complications and improve their quality of life.

Key words: 
Deglutition disorders ;  Rehabilitation
血清蛋白质异常的临床解读
Authors: 贾玫
Journal: BMJ (2008)

总蛋白(TP)是血液中多种蛋白的总和,按结构分为两大类,即白蛋白(ALB)和球蛋白(GLB).白蛋白全部由肝细胞合成和分泌,相对分子量约65000,半衰期约为20 d;球蛋白合成的组织很多,组成成分复杂,它们的代谢规律和途径不同,在血清中的变化规律也不同,有时在白蛋白降低时球蛋白反而上升。
Olaparib sensitivity observed in metastatic pancreatic cancer (mPaC) with a wide spectrum of germline <i>BRCA1 </i>and <i>BRCA2 </i>mutations (gBRCAm).
Authors: Talia Golan, Hedy L. Kindler, Philipp Schatz, Teodora Goranova, Gershon Y. Locker, Karen Cui, Katia Schlienger, David McGuinness, J. Andrew Williams, Maria Orr, Thorsten Gutjahr, Yu-Zhen Liu
Journal: Journal of Clinical Oncology (2021)

420 Background: The POLO study (NCT02184195) showed that mPaC patients (pts) with a deleterious or suspected deleterious gBRCAm, and whose disease had not progressed during ≥16 weeks of first-line platinum-based chemotherapy, had significantly longer progression-free survival (PFS, primary endpoint) with maintenance olaparib vs placebo: median 7.4 vs 3.8 months, hazard ratio (HR) 0.53; P= 0.004. PFS benefit was observed in pts with g BRCA1m (HR 0.40) and g BRCA2m (HR 0.63). The POLO study represents the largest BRCAm prevalence study in pancreatic cancer . We report additional exploratory analysis to further characterize patient gBRCAm profiles, including the relationship with efficacy. Methods: Pts were enrolled based on either a previously identified gBRCAm status from a local test result and subsequently confirmed by central testing, or a prospectively identified gBRCAm. Pts received maintenance olaparib 300 mg twice daily (tablet) or placebo. PFS was assessed by blinded independent central review (modified RECIST v1.1). Results: Of 3194 prospectively screened pts, a valid BRCA test result was obtained for 3175 (99%) from 12 countries; gBRCAm prevalence was 6.2% in pts not previously known to harbor a gBRCAm (196/3175; 1.6% g BRCA1m, 4.5% g BRCA2m). In countries (n = 8) with &gt; 100 pts prospectively tested, highest gBRCAm prevalence was 9.2% (USA) and lowest 4.0% (Spain). Prevalence by race ( &gt; 100 pts); 6.4% Caucasian, 4.6% Asian. In total, 154 pts with a gBRCAm satisfied all eligibility criteria and were randomized (106 prospectively tested and 48 by local test [44/48 subsequently confirmed by Myriad testing]). 37/154 (24%) randomized pts carried a common Ashkenazi Jewish founder mutation, the majority being from Israel (21 pts). From a total of 151 variants, frameshift mutations were most frequent (g BRCA1m 69.6%, g BRCA2m 71.4%) followed by nonsense mutations (g BRCA1m 6.5%, g BRCA2m 17.1%). The efficacy (PFS) of olaparib vs placebo in the different subgroups are shown in the table. Conclusions: In pts with mPaC enrolled in POLO, g BRCA2m were more prevalent than g BRCA1m and mutation type was predominantly frameshift. PFS benefit was consistent across a heterogenous spectrum of gBRCAm and with the previously reported full analysis set. Clinical trial information: NCT02184195. [Table: see text]
Training of general practitioner with special interest in UK
Authors: Ying Liu, Yan Qiu
Journal: BMJ (2016)

There are still problems in seamless connection between general practitioners and specialists in Chinese health service system, which hamper the implementation of continuous service in general practice. To train general practitioner with special interest (GPwSI) may be one of the approaches to solve the problem. In this article, we review the current status and effect of training for general practitioner with special interest in UK, and related issues to be solved in future. Hopefully these would be relevant to training of general practitioner with special interest in China.


Key words: 
General practitioner with special interest; Training
Prognosis and Treatment of Non–Small Cell Lung Cancer in the Age of Deep Learning
Authors: Frederick Matthew Howard, Alexander T. Pearson
Journal: JAMA Network Open (2020)

Yunlang She, MD; Zhuochen Jin, BS; Junqi Wu, MD; Jiajun Deng, MD; Lei Zhang, MD; Hang Su, MD; Gening Jiang, MD; Haipeng Liu, PhD; Dong Xie, MD, PhD; Nan Cao, PhD; Yijiu Ren, MD; Chang Chen, MD, PhD